561 808

Cited 0 times in

Cited 0 times in

3 '-Sialyllactose Protects SW1353 Chondrocytic Cells From Interleukin-1 beta-Induced Oxidative Stress and Inflammation

DC Field Value Language
dc.contributor.authorBaek, Ahreum-
dc.contributor.authorJung, So Hee-
dc.contributor.authorPyo, Soonil-
dc.contributor.authorKim, Soo Yeon-
dc.contributor.authorJo, Seongmoon-
dc.contributor.authorKim, Lila-
dc.contributor.authorLee, Eun Young-
dc.contributor.authorKim, Sung Hoon-
dc.contributor.authorCho, Sung-Rae-
dc.date.accessioned2021-05-26T16:52:57Z-
dc.date.available2021-05-26T16:52:57Z-
dc.date.created2021-07-06-
dc.date.issued2021-04-
dc.identifier.issn1663-9812-
dc.identifier.urihttps://ir.ymlib.yonsei.ac.kr/handle/22282913/182878-
dc.description.abstractOsteoarthritis (OA) is a major degenerative joint disease. Oxidative stress and inflammation play key roles in the pathogenesis of OA. 3 '-Sialyllactose (3 '-SL) is derived from human milk and is known to regulate a variety of biological functions related to immune homeostasis. This study aimed to investigate the therapeutic mechanisms of 3 '-SL in interleukin-1 beta (IL-1 beta)-treated SW1353 chondrocytic cells. 3 '-SL potently suppressed IL-1 beta-induced oxidative stress by increasing the levels of enzymatic antioxidants. 3 '-SL significantly reversed the IL-1 beta mediated expression levels of reactive oxygen species in IL-1 beta-stimulated chondrocytic cells. In addition, 3 '-SL could reverse the increased levels of inflammatory markers such as nitrite, prostaglandin E2, inducible nitric oxide synthase, cyclooxygenase-2, IL-1 beta, and IL-6 in IL-1 beta-stimulated chondrocytic cells. Moreover, 3 '-SL significantly inhibited the apoptotic process, as indicated by the downregulation of the pro-apoptotic protein Bax, upregulation of the anti-apoptotic protein Bcl-2 expression, and significant reduction in the number of TUNEL-positive cells in the IL-1 beta-treated chondrocytic cells. Furthermore, 3 '-SL reversed cartilage destruction by decreasing the release of matrix metalloproteinases (MMP), such as MMP1, MMP3, and MMP13. In contrast, 3 '-SL significantly increased the expression levels of matrix synthesis proteins, such as collagen II and aggrecan, in IL-1 beta-treated chondrocytic cells. 3 '-SL dramatically suppressed the activation of mitogen-activated protein kinases (MAPK) and phosphatidylinositol-3-kinase (PI3K)/protein kinase B (AKT)/nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) signaling pathways, which are related to the pathogenesis of OA. Taken together, our data suggest that 3 '-SL alleviates IL-1 beta-induced OA pathogenesis via inhibition of activated MAPK and PI3K/AKT/NF-kappa B signaling cascades with the downregulation of oxidative stress and inflammation. Therefore, 3 '-SL has the potential to be used as a natural compound for OA therapy owing to its ability to activate the antioxidant defense system and suppress inflammatory responses.-
dc.description.statementOfResponsibilityopen-
dc.languageEnglish-
dc.publisherFrontiers Media-
dc.relation.isPartOfFRONTIERS IN PHARMACOLOGY-
dc.relation.isPartOfFRONTIERS IN PHARMACOLOGY-
dc.rightsCC BY-NC-ND 2.0 KR-
dc.title3 '-Sialyllactose Protects SW1353 Chondrocytic Cells From Interleukin-1 beta-Induced Oxidative Stress and Inflammation-
dc.typeArticle-
dc.contributor.collegeCollege of Medicine (의과대학)-
dc.contributor.departmentDept. of Rehabilitation Medicine (재활의학교실)-
dc.contributor.googleauthorBaek, Ahreum-
dc.contributor.googleauthorJung, So Hee-
dc.contributor.googleauthorPyo, Soonil-
dc.contributor.googleauthorKim, Soo Yeon-
dc.contributor.googleauthorJo, Seongmoon-
dc.contributor.googleauthorKim, Lila-
dc.contributor.googleauthorLee, Eun Young-
dc.contributor.googleauthorKim, Sung Hoon-
dc.contributor.googleauthorCho, Sung-Rae-
dc.identifier.doi10.3389/fphar.2021.609817-
dc.relation.journalcodeJ03340-
dc.identifier.eissn1663-9812-
dc.subject.keywordosteoarthritis-
dc.subject.keyword3&apos-
dc.subject.keyword-
dc.subject.keyword-sialyllactose-
dc.subject.keywordoxidative stress-
dc.subject.keywordinflammation-
dc.subject.keywordapoptosis-
dc.subject.keywordmatrix metalloproteinases-
dc.contributor.alternativeNameCho, Sung Rae-
dc.contributor.affiliatedAuthorBaek, Ahreum-
dc.contributor.affiliatedAuthorPyo, Soonil-
dc.contributor.affiliatedAuthorJo, Seongmoon-
dc.contributor.affiliatedAuthorCho, Sung-Rae-
dc.identifier.scopusid2-s2.0-85104973638-
dc.identifier.wosid000643863300001-
dc.citation.volume12-
dc.identifier.bibliographicCitationFRONTIERS IN PHARMACOLOGY, Vol.12, 2021-04-
dc.identifier.rimsid70622-
dc.type.rimsART-
dc.description.journalClass1-
dc.description.journalClass1-
dc.subject.keywordAuthorosteoarthritis-
dc.subject.keywordAuthor3&apos-
dc.subject.keywordAuthor-
dc.subject.keywordAuthor-sialyllactose-
dc.subject.keywordAuthoroxidative stress-
dc.subject.keywordAuthorinflammation-
dc.subject.keywordAuthorapoptosis-
dc.subject.keywordAuthormatrix metalloproteinases-
dc.type.docTypeArticle-
dc.description.isOpenAccessN-
dc.description.journalRegisteredClassscie-
dc.description.journalRegisteredClassscopus-
dc.relation.journalWebOfScienceCategoryPharmacology & Pharmacy-
dc.relation.journalResearchAreaPharmacology & Pharmacy-
dc.identifier.articleno609817-
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Rehabilitation Medicine (재활의학교실) > 1. Journal Papers

qrcode

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.